Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer's disease

Alzheimer disease (AD) is the most common form of senile dementia, with no effective treatment available. In a study appearing online on August 11 in advance of print publication of the September 1 issue of the Journal of Clinical Investigation, Howard Weiner and colleagues from Harvard describe a novel immunologic approach for the treatment of AD.

Previous studies utilizing immunization against Abeta, a key pathogenic player in AD, to generate antibodies against Abeta were discontinued because of unacceptable side effects in AD patients.

Here, the researchers use a specific nasal vaccination to decrease AD burden in mice. The vaccine consists of an FDA-approved drug currently used to treat multiple sclerosis (called glatiramer acetate) plus a recently developed nasal adjuvant that has been shown to be safe in humans and activates microglia, cells which then clear beta-amyloid in the brain without evidence of toxic effects.

The findings have both basic and clinically relevant implications. The discovery of a non-antibody mediated method to clear Abeta could be used as a treatment for patients who already are showing signs of AD. Moreover, the compounds used have already been safely tested in humans.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study: Subconscious changes in day-to-day movements can predict Alzheimer’s disease